Drugs / Thymopentin

Trials 9

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT06112041 Oct 2023 → Oct 2026 expected carcinoma Second Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 2 NCT00002332 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00460681 Feb 2007 → Feb 2012 hepatocellular carcinoma Fudan University Unknown No outcome recorded
Phase 3 NCT00002109 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
Phase not applicable5 trials
— NCT00002289 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
— NCT00002066 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
— NCT00002051 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
— NCT00002050 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded
— NCT00002049 — HIV infectious disease Immunobiology Research Institute Completed No outcome recorded

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Thymopentin ClinicalTrials.gov intervention name — accepted as the source's own label NCT06112041 ↗
8

NCT00002066 ↗

NCT00002332 ↗

NCT00460681 ↗

NCT00002049 ↗

NCT00002051 ↗

NCT00002050 ↗

NCT00002109 ↗

NCT00002289 ↗

Known as Arg-lys-asp-val-tyr ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Hg-thymopentin ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Immunox ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as NSC-760116 ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as ORF 15244 ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Oristar thymopentin ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Pentapeptide-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Sh-pentapeptide-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Sintomodulina ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Thymopentine ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Thymopoetin 32-36-pentapeptide ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Thymopoietin 32-36 ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Thymopoietin pentapeptide ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Timopentina ChEMBL registry synonym — accepted as the source's own label CHEMBL156025 ↗
Known as Timunox “Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation.” NCT00002049 ↗
4

“Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation.” NCT00002050 ↗

“Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation.” NCT00002289 ↗

“Examine the ability of thymopentin (Timunox) to:” NCT00002066 ↗

“Examine the ability of thymopentin (Timunox) to:” NCT00002051 ↗

Known as TP5 “Immunomodulatory peptides, like thymopentin (TP5), may act as immunomodulatory agents in cancer chemotherapy.” NCT00460681 ↗
Modality Peptide “Immunomodulatory peptides, like thymopentin (TP5), may act as immunomodulatory agents in cancer chemotherapy.” NCT00460681 ↗
Route Subcutaneous “Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks.” NCT00002332 ↗